Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GILD has clawed back from last week's drop to $144.23, closing Tuesday at $147.92, yet the rebound arrives with a quiet but notable build in short interest that is worth tracking into the November 6 earnings date.
The most interesting development this week is not the price recovery itself but what has happened in the lending market alongside it. Short interest jumped 20% in a single week, rising from around 18.3 million shares to just under 22 million, putting it back near the levels seen in mid-September before a sharp step-down. At 1.77% of free float, the absolute level remains low. This is not a heavily shorted stock by any measure, and borrow availability is essentially unlimited, with over 1.2 billion shares available to lend. Cost to borrow has also eased, falling to 0.51% from above 1.5% earlier this month. The lending market is loose, and the short-score reading of 33 reflects that. But the directional move in short interest is clear: positions are being rebuilt after a cleanup, and the timing, just weeks before results, is worth noting.
Options positioning has drifted modestly more defensive without becoming alarming. The put/call ratio has edged up to 0.58, about 1.3 standard deviations above its 20-day average of 0.54. That is not an extreme read, particularly given the 52-week high sits at 0.92, but the direction matches the short interest story: caution is growing, not fear. The ORTEX short score ticked from 31.4 to 33.1 over the past week, a small but consistent move higher.
The Street picture has been well-documented in the prior note and has not changed materially since. JP Morgan, Truist, and Morgan Stanley all moved targets within the past week, with the net bias tilting upward. The mean target is $159.58, implying roughly 8% upside from current levels. The bull case centres on Biktarvy's durability, the FDA acceptance of the 300mg once-weekly oral Yeztugo for a February 2027 PDUFA date, and oncology optionality through Trodelvy and anito-cel. Bears flag generic exposure in the HIV franchise, pricing pressure risk, and what they see as an overly optimistic consensus on Yeztugo's long-term PrEP penetration, with one camp modelling $3.9 billion in peak sales against a $7 billion Street consensus. Factor scores lean toward quality: EPS momentum ranks in the 93rd to 95th percentile on both 30-day and 90-day windows, and the dividend score sits at the 97th percentile, though the dividend history in the data is stale and the current yield should be verified separately.
Institutional ownership is concentrated in the usual passive block. BlackRock holds 9.8% and added 2.8 million shares in the quarter to September 30. T. Rowe Price added 3.8 million shares to reach 2.4% of shares outstanding, the most active buyer among the top holders over the period. No 13D activist is on the register. All 13G filings reflect passive positions as last disclosed, and stakes can move below 5% without a further filing.
The CEO, Daniel O'Day, sold $2.2 million of stock on October 1 under a pre-arranged 10b5-1 plan. Planned sales carry less signal than discretionary ones, and the CFO made a smaller plan-based sale on September 15. Neither transaction changes the ownership picture, but combined with the short interest build, it adds one more thread of caution into a stock that is otherwise tracking higher.
The key question heading into November 6 is whether the short rebuild reflects genuine conviction around a miss or simply pre-earnings positioning that unwinds quickly. With availability ample, borrowing cheap, and targets well above the current price, the market's caution looks considered rather than urgent.
See the live data behind this article on ORTEX.
Open GILD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
